Form 4: Nuvation Bio CMO Sells Shares After Option Exercise

Nuvation Bio's Chief Medical Officer, Dongfang Liu, exercised stock options and subsequently sold a portion of Class A Common Stock in late November 2025.

Summary

• Dongfang Liu, Chief Medical Officer of Nuvation Bio Inc., reported transactions involving the company's Class A Common Stock.
• On November 25, 2025, Liu exercised options to acquire 10,000 shares of Class A Common Stock at an exercise price of $3.61 per share.
• Immediately following the option exercise on November 25, 2025, Liu sold 10,000 shares of Class A Common Stock at a price of $7.50 per share.
• On November 26, 2025, Liu again exercised options to acquire 10,000 shares of Class A Common Stock at an exercise price of $3.61 per share.
• Immediately following the option exercise on November 26, 2025, Liu sold 10,000 shares of Class A Common Stock at a price of $8.00 per share.
• Following these transactions, Liu's direct beneficial ownership of non-derivative Class A Common Stock remained at 18,000 shares.
• The number of stock options beneficially owned by Liu decreased from 480,000 to 460,000 after these exercises.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to insider selling, even though it follows option exercises and is likely part of a pre-planned strategy. While the insider profited, the reduction in direct equity holdings can sometimes be viewed cautiously by investors.

Positives

• The Chief Medical Officer realized a significant profit from exercising options at $3.61 and selling shares at $7.50 and $8.00, indicating personal financial gain.
• The transactions were made pursuant to a Rule 10b5-1(c) plan, suggesting pre-planned sales rather than a reaction to immediate company news.

Negatives

• The Chief Medical Officer reduced their direct equity exposure by selling 20,000 shares of Class A Common Stock over two days, which could be interpreted as a slight negative signal by some investors.

Future Outlook

This Form 4 filing reports past insider transactions and does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing is a standard report of insider trading activity and does not provide specific insights into broader industry trends or competitive landscape. Insider transactions are common in the biotechnology and pharmaceutical sectors, where executive compensation often includes significant equity components.

Stakeholder Impact

• Shareholders may interpret the insider selling as a signal, potentially influencing their perception of the stock's short-term prospects, although the sales were pre-planned under a Rule 10b5-1 plan.

Key Dates

Keywords

Nuvation Bio Inc., NUVB, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Chief Medical Officer, Dongfang Liu, Beneficial Ownership